Comparing antiviral treatments for kidney transplants from hepatitis C-infected donors to uninfected recipients
Official title: A Randomized Controlled Trial of Prophylaxis with Direct-acting Antivirals for Kidney Transplantation from Hepatitis C virus-infected donor to Uninfected Recipients (PREVENT-HCV)
Funded at Johns Hopkins University · NIH-11043309 · Data updated 2026-11-12
This study is looking at the best way to use new medicines to prevent hepatitis C in kidney transplant patients when the donor has the virus, comparing whether it's better to give the medicine before or after the transplant, and it's for people who are getting a kidney transplant from a donor with hepatitis C.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | March 25, 2022 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $1,359,557 |
| NIH project number | 5U01AI157931-04 |
| Project ID | NIH-11043309 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who require a kidney transplant and are willing to receive a kidney from a hepatitis C-infected donor.
✕Less likely to help
Patients who are already infected with hepatitis C or those who do not require a kidney transplant will not benefit from this research.
What this research studies
This research investigates the best approach to using direct-acting antivirals (DAAs) in kidney transplantation from donors infected with hepatitis C to recipients who are not infected. It aims to compare two strategies: giving DAAs as a preventive measure before transplantation versus treating the infection after the transplant. The study will involve 120 kidney transplants across six centers and will assess the safety and effectiveness of both approaches, as well as monitor potential complications. By determining the optimal treatment strategy, the research seeks to improve outcomes for kidney transplant recipients.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective kidney transplants from hepatitis C-infected donors, ultimately increasing the availability of donor kidneys.
How similar studies have gone: Previous research has shown early success with similar approaches in using direct-acting antivirals for hepatitis C in transplant settings, but this specific comparison has not been tested before.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Durand, Christine Marie — Johns Hopkins University
- Study coordinator: Durand, Christine Marie
Related research
Other NIH-funded projects on the same topics.
-
Preventing hepatitis C after receiving a kidney from an HCV-positive donor
This compares two ways of giving hepatitis C antivirals to people getting a kidney from an HCV-positive donor to find which best prevents infection and complications.
-
Cognitive behavioral therapy and trazodone for insomnia phenotypes with high blood pressure
A clinical study tests how CBT-I and the sleep drug trazodone work for adults with insomnia and high blood pressure, focusing on a specific sleep duration pattern.
-
Shorter antifungal treatment for kids with candidemia
A multi-center pediatric trial tests whether a shorter, 7 extra days of antifungal therapy after an initial 7 days is just as good as the standard 14-day approach for kids with candidemia who are improving on echinocandin therapy.
-
Short Course vs Standard Course Antifungal Therapy for Pediatric Candidemia
This study tests whether a shorter 7-day total antifungal treatment after an initial 7 days of echinocandin therapy is as effective as the usual 14-day course for children with candidemia.
-
Shorter antifungal treatment for kids with candidemia
A multi-center study tests whether kids with candidemia can finish treatment earlier after an initial week of antifungal therapy than the standard two weeks total.
-
Shorter antifungal treatment for kids with candidemia
This study tests whether children with candidemia can finish treatment after 7 days of an echinocandin if they are improving, instead of completing a full 14 days.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.